Welcome to our dedicated page for BioLineRX news (Ticker: BLRX), a resource for investors and traders seeking the latest updates and insights on BioLineRX stock.
BioLineRx Ltd. (NASDAQ: BLRX) is a commercial-stage biopharmaceutical company based in Modi'in, Israel, with operations extending to the United States. The company specializes in developing life-changing therapies for oncology and rare diseases. BioLineRx's flagship product, APHEXDA® (motixafortide), has gained approval in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma patients.
Currently, the company is advancing a robust pipeline of investigational medicines targeting sickle cell disease, pancreatic cancer, and other solid tumors. One of their notable clinical-stage therapeutic candidates is motixafortide (BL-8040), a novel peptide showing promise in stem-cell mobilization and solid tumors. Another key candidate is AGI-134, an immuno-oncology agent dedicated to treating solid tumors.
BioLineRx recently announced definitive agreements with institutional investors for the issuance and sale of its American Depositary Shares (ADSs) and warrants. This equity transaction, combined with financial resources from an existing debt facility, positions the company well for the commercialization of APHEXDA and the advancement of its other pipeline programs. Additionally, the company is exploring motixafortide's potential in supporting gene therapy for sickle cell disease, collaborating with leaders in the gene therapy field such as St. Jude Children's Research Hospital and Washington University School of Medicine.
BioLineRx has also received recent notifications and presented new data at various esteemed conferences such as the American Society of Clinical Oncology (ASCO) and the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). These efforts underscore the company's commitment to bringing innovative therapies from the bench to the bedside.
To access more information about BioLineRx, visit their official website or follow them on Twitter and LinkedIn.
BioLineRx Ltd. (NASDAQ:BLRX) has appointed Dr. Tami Rachmilewitz as Chief Medical Officer, effective January 4, 2023. Dr. Rachmilewitz brings over 15 years of clinical development experience, previously holding leadership roles at VBL Therapeutics and other notable companies. Her expertise will support BioLineRx's upcoming initiatives, including the launch of APHEXDA® and the further development of the drug motixafortide across various therapeutic areas. This appointment aims to enhance the company's capabilities in bringing innovative treatments to cancer patients.
BioLineRx Ltd. (NASDAQ: BLRX) announced positive results from its Phase 1/2a study of AGI-134, an investigational cancer vaccine for unresectable metastatic solid tumors. The study met its primary endpoint of safety and tolerability, with no dose-limiting toxicities and a recommended dose of 200mg for further trials. Immune activity was also observed, with 29% of patients achieving stable disease. The company plans to publish full data analysis in 2023 and will consult its advisory board for next steps.
BioLineRx Ltd. (NASDAQ: BLRX) announced its participation in the 12th Annual LifeSci Partners Corporate Access Event occurring from January 9-11, 2023, in San Francisco, CA. Management will be available for one-on-one meetings on January 11, 2023. BioLineRx focuses on oncology, with its lead drug, motixafortide, showing promise in multiple studies, including a Phase 3 trial for multiple myeloma and a Phase 2a trial for pancreatic cancer. The FDA has accepted its NDA submission with a PDUFA date of September 9, 2023.
BioLineRx Ltd. announced the FDA's acceptance of its New Drug Application for APHEXDA® (motixafortide), aimed at mobilizing stem cells for multiple myeloma treatment, with a PDUFA target date of September 9, 2023. The company plans to independently commercialize APHEXDA® in the U.S., naming Holly May as President of BioLineRx USA. BioLineRx completed a $40 million debt financing and a $15 million equity offering to support the product launch. The company reported a net loss of $6.8 million for Q3 2022 and had $57.3 million in cash as of September 30, 2022.
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a biopharmaceutical company focused on oncology, will release its unaudited financial results for Q3 2022 on November 15, 2022, before U.S. markets open. The conference call, featuring CEO Philip Serlin, is scheduled for 10:00 a.m. EST on the same day. Interested parties can join by dialing +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally, or via webcast. A replay will be available two hours post-call. BioLineRx's lead program, motixafortide, has a PDUFA date of September 9, 2023.
BioLineRx Ltd. (NASDAQ: BLRX) announced that the FDA has accepted its New Drug Application (NDA) for APHEXDA® (motixafortide), targeting improved stem cell mobilization in multiple myeloma patients. The NDA is based on the GENESIS Phase 3 trial, which met all endpoints with high statistical significance. A PDUFA action date is set for September 9, 2023. The company is preparing for a robust commercial launch, highlighting a potential to enhance patient outcomes and reduce healthcare resource usage.
BioLineRx Ltd. (NASDAQ/TASE: BLRX) received a notification letter from Nasdaq indicating non-compliance with the minimum bid price requirement, as the closing bid price for its ADSs was below USD $1.00 for 30 consecutive trading days. The company has until May 1, 2023, to regain compliance, with the possibility of an extension if necessary. This notice does not immediately affect the company's listing, and they will continue operations, focusing on the potential launch of APHEXA® for treating multiple myeloma patients.
BioLineRx Ltd. (NASDAQ: BLRX) announced significant findings related to motixafortide, a candidate for stem cell mobilization in multiple myeloma patients. The full pharmacoeconomic study shows cost benefits when using motixafortide with G-CSF compared to plerixafor with G-CSF, demonstrating reduced healthcare resource utilization and higher successful mobilization rates. Additionally, a Phase 1 trial design for using motixafortide in gene therapy for sickle cell disease will also be presented at the ASH Annual Meeting from December 10-13, 2022.
BioLineRx Ltd. (NASDAQ: BLRX) has announced its plan for independent U.S. commercialization of APHEXDA (Motixafortide) for stem cell mobilization in multiple myeloma patients, contingent on FDA approval. Veteran product leader Holly May has been appointed as President, BioLineRx USA. The company aims to build a targeted sales force to engage with transplant centers, projecting a $360 million annual market opportunity. The recent NDA submission follows positive results from the GENESIS Phase 3 trial. A webinar is scheduled for September 28 to discuss the launch strategy.
BioLineRx Ltd. (NASDAQ: BLRX) announced a registered direct offering of 13,636,365 American Depositary Shares (ADSs) and warrants at a price of $1.10 per ADS, projected to raise gross proceeds of $15 million. The offering is expected to close around September 21, 2022. The funds will support the commercial launch of Motixafortide for multiple myeloma and other corporate needs, including clinical trials. The warrants have an exercise price of $1.15 per ADS and expire five years post-issuance.
FAQ
What is the current stock price of BioLineRX (BLRX)?
What is the market cap of BioLineRX (BLRX)?
What does BioLineRx Ltd. specialize in?
What is APHEXDA®?
What are some of BioLineRx's key therapeutic candidates?
Where is BioLineRx Ltd. headquartered?
Who are BioLineRx's collaboration partners for gene therapy?
What recent financial actions has BioLineRx taken?
What was discussed at the recent conferences BioLineRx attended?
What is AGI-134?
Can I invest in BioLineRx Ltd.?
Where can I find more information about BioLineRx?
